Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Vilanterol vs Salmeterol in COPD
NCT00372112Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of vilanterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) up to 17 days. Started Nov 2006; status: completed.
02
Drugs
vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00372112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372112.